Zoran Zdraveski - Aug 23, 2024 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Chief Legal and Strategy Officer
Signature
/s/ Zoran Zdraveski
Stock symbol
TCRX
Transactions as of
Aug 23, 2024
Transactions value $
-$420,595
Form type
4
Date filed
8/27/2024, 06:46 PM
Previous filing
Jun 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCRX Voting Common Stock Options Exercise $266K +54.9K +449.37% $4.85 67.1K Aug 23, 2024 Direct F1
transaction TCRX Voting Common Stock Options Exercise $81.8K +25K +37.25% $3.27 92.1K Aug 23, 2024 Direct
transaction TCRX Voting Common Stock Options Exercise $23.8K +13.1K +14.25% $1.81 105K Aug 23, 2024 Direct
transaction TCRX Voting Common Stock Options Exercise $160K +64.2K +60.97% $2.49 169K Aug 23, 2024 Direct
transaction TCRX Voting Common Stock Sale -$952K -165K -97.22% $5.78 4.72K Aug 23, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Options Exercise $0 -54.9K -64.58% $0.00 30.1K Aug 23, 2024 Voting Common Stock 54.9K $4.85 Direct F3
transaction TCRX Stock Option (Right to Buy) Options Exercise $0 -25K -50% $0.00 25K Aug 23, 2024 Voting Common Stock 25K $3.27 Direct F4
transaction TCRX Stock Option (Right to Buy) Options Exercise $0 -13.1K -37.5% $0.00 21.9K Aug 23, 2024 Voting Common Stock 13.1K $1.81 Direct F5
transaction TCRX Stock Option (Right to Buy) Options Exercise $0 -64.2K -14.92% $0.00 366K Aug 23, 2024 Voting Common Stock 64.2K $2.49 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 7,500 shares of Voting Common Stock acquired under the TScan Therapeutics, Inc. 2021 Employee Stock Purchase Plan on December 31, 2022.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.56 to $5.91, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the Issuer, any security holder of the Issuer, or the SEC staff upon request.
F3 The shares subject to this option vest over 4 years of service following January 18, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
F4 The shares subject to this option vest over 4 years of service following July 25, 2022, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
F5 The shares subject to this option vest over 4 years of service following February 2, 2023, with 25% vesting upon completion of 1 year of continuous service to the Issuer and the balance vesting in 36 equal monthly installments thereafter.
F6 220,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 210,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023.

Remarks:

Chief Legal and Strategy Officer